Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: RECTAL NEOPLASMS - DRUG THERAPY , . Treffer: 36

2020

Moik, F; Posch, F; Grilz, E; Scheithauer, W; Pabinger, I; Prager, G; Ay, C Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Thromb Res. 2020; 187:9-17 Doi: 10.1016/j.thromres.2020.01.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2019

Barth, DA; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Stotz, M; Gerger, A Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Clin Transl Oncol. 2019; 21(8):1034-1043 Doi: 10.1007/s12094-019-02037-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Eisterer, W; Piringer, G; DE Vries, A; Öfner, D; Greil, R; Tschmelitsch, J; Samonigg, H; Sölkner, L; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Anticancer Res. 2017; 37(5):2683-2691 Doi: 10.21873/anticanres.11617 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Goblirsch, M; Richtig, G; Slaby, O; Berindan-Neagoe, I; Gerger, A; Pichler, M MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.
Pharmacogenomics. 2017; 18(10):1027-1038 Doi: 10.2217/pgs-2017-0004
Web of Science PubMed FullText FullText_MUG

 

Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415 Doi: 10.1186/s12885-017-3392-4 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Schütte, M; Risch, T; Abdavi-Azar, N; Boehnke, K; Schumacher, D; Keil, M; Yildiriman, R; Jandrasits, C; Borodina, T; Amstislavskiy, V; Worth, CL; Schweiger, C; Liebs, S; Lange, M; Warnatz, HJ; Butcher, LM; Barrett, JE; Sultan, M; Wierling, C; Golob-Schwarzl, N; Lax, S; Uranitsch, S; Becker, M; Welte, Y; Regan, JL; Silvestrov, M; Kehler, I; Fusi, A; Kessler, T; Herwig, R; Landegren, U; Wienke, D; Nilsson, M; Velasco, JA; Garin-Chesa, P; Reinhard, C; Beck, S; Schäfer, R; Regenbrecht, CR; Henderson, D; Lange, B; Haybaeck, J; Keilholz, U; Hoffmann, J; Lehrach, H; Yaspo, ML Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors.
Nat Commun. 2017; 8(2):14262-14262 Doi: 10.1038/ncomms14262 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Bonin, S; Donada, M; Bussolati, G; Nardon, E; Annaratone, L; Pichler, M; Chiaravalli, AM; Capella, C; Hoefler, G; Stanta, G A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
Tumour Biol. 2016; 37(6):7295-7303 Doi: 10.1007/s13277-015-4543-3
Web of Science PubMed FullText FullText_MUG

 

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): Doi: 10.3390/ijms17122011 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Perakis, SO; Thomas, JE; Pichler, M Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
Adv Exp Med Biol. 2016; 937(4):183-204 Doi: 10.1007/978-3-319-42059-2_10
Web of Science PubMed FullText FullText_MUG

 

2015

Bochis, OV; Irimie, A; Pichler, M; Berindan-Neagoe, I The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
J Gastrointestin Liver Dis. 2015; 24(2):225-234 Doi: 10.15403/jgld.2014.1121.242.skp2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Eisner, F; Pichler, M; Goletz, S; Stoeger, H; Samonigg, H A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.
J Clin Pathol. 2015; 68(12):1044-1046 Doi: 10.1136/jclinpath-2015-202996 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Kaczirek, K; Ciuleanu, TE; Vrbanec, D; Marton, E; Messinger, D; Liegl-Atzwanger, B; Wrba, F; Knittelfelder, R; Lindner, E; Zielinski, CC; Streubel, B; Brodowicz, T FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Clin Colorectal Cancer. 2015; 14(2):91-98 Doi: 10.1016/j.clcc.2014.12.003
Web of Science PubMed FullText FullText_MUG

 

Thomas, J; Ohtsuka, M; Pichler, M; Ling, H MicroRNAs: Clinical Relevance in Colorectal Cancer.
Int J Mol Sci. 2015; 16(12):28063-28076 Doi: 10.3390/ijms161226080 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Benhaim, L; Gerger, A; Bohanes, P; Paez, D; Wakatsuki, T; Yang, D; Labonte, MJ; Ning, Y; El-Khoueiry, R; Loupakis, F; Zhang, W; Laurent-Puig, P; Lenz, HJ Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
Pharmacogenomics J. 2014; 14(2):135-141 Doi: 10.1038/tpj.2013.21
Web of Science PubMed FullText FullText_MUG

 

Cota, C; Lora, V; Facchetti, F; Cerroni, L Localized post-radiation Kaposi sarcoma in a renal transplant immunosuppressed patient.
Am J Dermatopathol. 2014; 36(3):270-273 Doi: 10.1097/DAD.0b013e3182918f36 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Mohan, S; Heitzer, E; Ulz, P; Lafer, I; Lax, S; Auer, M; Pichler, M; Gerger, A; Eisner, F; Hoefler, G; Bauernhofer, T; Geigl, JB; Speicher, MR Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.
PLoS Genet. 2014; 10(3):e1004271-e1004271 Doi: 10.1371/journal.pgen.1004271 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pichler, M; Winter, E; Ress, AL; Bauernhofer, T; Gerger, A; Kiesslich, T; Lax, S; Samonigg, H; Hoefler, G miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.
J Clin Pathol. 2014; 67(3):198-203 Doi: 10.1136/jclinpath-2013-201904
Web of Science PubMed FullText FullText_MUG

 

Ress, AL; Stiegelbauer, V; Schwarzenbacher, D; Deutsch, A; Perakis, S; Ling, H; Ivan, C; Calin, GA; Rinner, B; Gerger, A; Pichler, M Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
Oncotarget. 2014; 5(18):8492-8502 Doi: 10.18632/oncotarget.2329 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Smolle, M; Uranitsch, S; Gerger, A; Pichler, M; Haybaeck, J Current status of long non-coding RNAs in human cancer with specific focus on colorectal cancer.
Int J Mol Sci. 2014; 15(8):13993-14013 Doi: 10.3390/ijms150813993 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735 Doi: 10.3748/wjg.v20.i33.11727 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Dijkstra, JR; Opdam, FJ; Boonyaratanakornkit, J; Schönbrunner, ER; Shahbazian, M; Edsjö, A; Hoefler, G; Jung, A; Kotsinas, A; Gorgoulis, VG; Lpez-Ros, F; de Stricker, K; Rouleau, E; Biesmans, B; van Krieken, JH Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
J Mol Diagn. 2012; 14(3):187-191 Doi: 10.1016/j.jmoldx.2012.01.002 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Pichler, M; Winter, E; Stotz, M; Eberhard, K; Samonigg, H; Lax, S; Hoefler, G; Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
Br J Cancer. 2012; 106(11):1826-1832 Doi: 10.1038/bjc.2012.175 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Gerger, A; El-Khoueiry, A; Zhang, W; Yang, D; Singh, H; Bohanes, P; Ning, Y; Winder, T; Labonte, MJ; Wilson, PM; Benhaim, L; Paez, D; El-Khoueiry, R; Absenger, G; Lenz, HJ Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Clin Cancer Res. 2011; 17(17):5783-5792 Doi: 10.1158/1078-0432.CCR-11-1115 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mikalauskas, S; Mikalauskiene, L; Bruns, H; Nickkholgh, A; Hoffmann, K; Longerich, T; Strupas, K; Büchler, MW; Schemmer, P Dietary glycine protects from chemotherapy-induced hepatotoxicity.
Amino Acids. 2011; 40(4):1139-1150 Doi: 10.1007/s00726-010-0737-6
Web of Science PubMed FullText FullText_MUG

 

Ofner, D; Devries, AF; Schaberl-Moser, R; Greil, R; Rabl, H; Tschmelitsch, J; Zitt, M; Kapp, KS; Fastner, G; Keil, F; Eisterer, W; Jäger, R; Offner, F; Gnant, M; Thaler, J; TAKO 05/ABCSG R-02 Trial Investigators Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Strahlenther Onkol. 2011; 187(2):100-107 Doi: 10.1007/s00066-010-2182-6
Web of Science PubMed FullText FullText_MUG

 

Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nösslinger, T; Mayrbäurl, B; Thaler, J Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Ann Oncol. 2011; 22(2): 486-487. Doi: 10.1093/annonc/mdq744 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Winder, T; Zhang, W; Yang, D; Ning, Y; Bohanes, P; Gerger, A; Wilson, P; Pohl, A; Mauro, DJ; Langer, C; Rowinsky, EK; Lenz, HJ Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients.
Clin Cancer Res. 2010; 16(22):5591-5602 Doi: 10.1158/1078-0432.CCR-10-2092 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Zhang, W; Azuma, M; Lurje, G; Gordon, MA; Yang, D; Pohl, A; Ning, Y; Bohanes, P; Gerger, A; Winder, T; Hollywood, E; Danenberg, KD; Saltz, L; Lenz, HJ Molecular Predictors of Combination Targeted Therapies (Cetuximab, Bevacizumab) in Irinotecan-Refractory Colorectal Cancer (BOND-2 Study).
Anticancer Res. 2010; 30(10):4209-4217
Web of Science PubMed

 

2008

van Krieken, JH; Jung, A; Kirchner, T; Carneiro, F; Seruca, R; Bosman, FT; Quirke, P; Fléjou, JF; Plato Hansen, T; de Hertogh, G; Jares, P; Langner, C; Hoefler, G; Ligtenberg, M; Tiniakos, D; Tejpar, S; Bevilacqua, G; Ensari, A KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
Virchows Arch. 2008; 453(5): 417-431. Doi: 10.1007/s00428-008-0665-y [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

D'Angelica, M; Kornprat, P; Gonen, M; Chung, KY; Jarnagin, WR; DeMatteo, RP; Fong, Y; Kemeny, N; Blumgart, LH; Saltz, LB Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
Ann Surg Oncol. 2007; 14(2):759-765 Doi: 10.1245/s10434-006-9074-0
Web of Science PubMed FullText FullText_MUG

 

Kornprat, P; Jarnagin, WR; Gonen, M; DeMatteo, RP; Fong, Y; Blumgart, LH; D'Angelica, M Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy.
Ann Surg Oncol. 2007; 14(3):1151-1160 Doi: 10.1245/s10434-006-9068-y
Web of Science PubMed FullText FullText_MUG

 

2005

Filipits, M; Pohl, G; Rudas, M; Dietze, O; Lax, S; Grill, R; Pirker, R; Zielinski, CC; Hausmaninger, H; Kubista, E; Samonigg, H; Jakesz, R Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2005; 23(6):1161-1168 Doi: 10.1200/JCO.2005.03.033 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2002

Eckel, F; Schmelz, R; Adelsberger, H; Erdmann, J; Quasthoff, S; Lersch, C Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study
DEUT MED WOCHENSCHR 2002 127: 78-82. Doi: 10.1055/s-2002-19594
Web of Science PubMed FullText FullText_MUG

 

Lersch, C; Schmelz, R; Eckel, F; Erdmann, J; Mayr, M; Schulte-Frohlinde, E; Quasthoff, S; Grosskreutz, J; Adelsberger, H Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Clin Colorectal Cancer. 2002; 2(1): 54-58. Doi: 10.3816/CCC.2002.n.011
PubMed FullText FullText_MUG

 

1999

Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Eur J Cancer. 1999; 35(3):380-385 Doi: 10.1016%2FS0959-8049%2898%2900397-9
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1996

Cunningham, D; Zalcberg, JR; Rath, U; Oliver, I; van Cutsem, E; Svensson, C; Seitz, JF; Harper, P; Kerr, D; Perez-Manga, G Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Ann Oncol. 1996; 7(9):961-965 Doi: 10.1093/oxfordjournals.annonc.a010800 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum